Digestive System Neoplasms: Clinical Trials

21,862 trials for Digestive System Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8755 completed, 4634 unknown, 3339 recruiting, 1755 terminated. 7064 Phase 2, 5003 Not applicable, 3720 Phase 1, 1958 Phase 3, 420 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 27064Completed 2626, Unknown 1391, Recruiting 1057, Terminated 763, Not yet recruiting 452, Active not recruiting 430, Withdrawn 289, Suspended 39, Enrolling by invitation 17
Not applicable5003Completed 2011, Unknown 1175, Recruiting 771, Not yet recruiting 333, Terminated 286, Active not recruiting 217, Withdrawn 146, Enrolling by invitation 48, Suspended 16
Phase 13720Completed 1577, Recruiting 587, Terminated 536, Unknown 434, Active not recruiting 264, Withdrawn 145, Not yet recruiting 139, Suspended 31, Enrolling by invitation 7
Phase 31958Completed 748, Unknown 474, Recruiting 293, Terminated 168, Active not recruiting 126, Not yet recruiting 91, Withdrawn 45, Suspended 8, Enrolling by invitation 5
Phase 4420Completed 184, Unknown 119, Not yet recruiting 33, Recruiting 33, Terminated 26, Withdrawn 13, Active not recruiting 8, Enrolling by invitation 3, Suspended 1
Early Phase 1260Unknown 64, Completed 63, Recruiting 41, Terminated 30, Not yet recruiting 23, Withdrawn 17, Active not recruiting 14, Enrolling by invitation 5, Suspended 3

Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma
Phase 1 / Phase 2WithdrawnLisata Therapeutics, Inc.2030-01-012025-06-06
Adaptive Neoadjuvant Therapy for Esophageal Cancer
Neoadjuvant concurrent chemoradiotherapy - Esophageal Carcinoma, Neoadjuvant Therapy
Not applicableEnrolling by invitationCancer Hospital Chinese Academy of Medical Science, Shenzhen Center432028-03-012025-05-25
Improving Clinic Delivery of HIV-related Anal Health Services
PEACHES 2.0 Implementation Strategies - HIV, Gonorrhea
Not applicableNot yet recruitingAlbert Einstein College of Medicine82028-02-012026-10-13
The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp
Shared Decision Making using a Patient Decision Aid. - Shared Decision Making, Colonic Polyp
Phase 2Not yet recruitingVejle Hospital1102028-02-012026-04-30
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer
Phase 2SuspendedHoly Stone Healthcare Co., Ltd1002027-12-012026-09-18
Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer
intravoxel incoherent motion magnetic resonance imaging - Rectal Neoplasms, Prognosis
Not yet recruitingSichuan Cancer Hospital and Research Institute4002027-11-012025-12-08
Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms
Clinical Intervention or Procedure, Electronic Health Record Review, Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas - Pancreatic Neoplasm, Pancreatic Neuroendocrine Tumor
Not applicableEnrolling by invitationOhio State University Comprehensive Cancer Center122027-10-012026-10-13
DESIR. Evaluation of the Pre-therapeutic Activity of Dihydropyrimidine dEShydrogenase (DPD) in Patients With Cancer and/or Renal Failure
blood sampling, Blood sampling - Renal Impairment, Digestive Cancers
Not yet recruitingCentre Hospitalier Universitaire de Besancon7422027-10-012026-11-02
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Phase 2Not yet recruitingXiang-Qian1202027-09-012026-08-27
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
Rintatolimod - Pancreatic Cancer
Phase 2SuspendedAIM ImmunoTech Inc.902027-08-012026-08-19
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer
Phase 3Not yet recruitingTranscenta Therapeutics (Hangzhou) Co., Ltd.8202027-06-302026-09-29
Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
DN022150+AG( Stage I ), DN022150+AG(Stage II), placebo+AG(Stage II) - Pancreatic Cancer, Pancreatic Carcinoma
Phase 2 / Phase 3Not yet recruitingJiangxi Kvvit Pharmaceutical Co., Ltd.4652027-06-062026-06-18
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
Envafolimab plus Gemcitabine&Cisplatin, Gemcitabine&Cisplatin - Biliary Tract Neoplasms
Phase 2Not yet recruiting3D Medicines (Sichuan) Co., Ltd.1262027-06-012026-03-25
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)312027-06-012026-10-22
Immunotherapy Treating GI Cancer
engineered immune cells - Cancer
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002027-06-012026-11-02
SGA-OCRC: Prediction of 90-Day Major Adverse Postoperative Outcomes in Octogenarians With Resectable Colorectal Cancer
Octogenarian Patients With Non-metastatic Resectable Colorectal Cancer
Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine10002027-06-012026-10-29
ctDNA Observational Biomarker Validation Study for Evaluation of Esophageal Squamous Cell Carcinoma
Tumor-Informed ctDNA Assessment (Signatera™ Genome Assay) - Esophageal Squamous Cell Carcinoma (ESCC)
Not yet recruitingUniversity of Colorado, Denver1202027-06-012026-11-16
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
Tislelizumab - Cholangiocarcinoma, Biliary Tract Cancer (BTC)
Phase 2Not yet recruitingNational Cheng-Kung University Hospital352027-06-012026-11-17
Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
Balstilimab, Biopsy Procedure, Biospecimen Collection - Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8
Phase 2RecruitingNational Cancer Institute (NCI)202027-05-252026-09-29
CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
Phase 1Not yet recruitingCity of Hope Medical Center362027-05-062026-09-25

Showing 20 of 21862. Sign in to see all of them.

Narrower conditions

Colorectal Neoplasms (6148)  ·  Pancreatic Neoplasms (3690)  ·  Carcinoma, Hepatocellular (3389)  ·  Stomach Neoplasms (3193)  ·  Colonic Neoplasms (2382)  ·  Rectal Neoplasms (2246)  ·  Esophageal Neoplasms (1844)  ·  Liver Neoplasms (1296)  ·  Neoplasms (1197)  ·  Breast Neoplasms (1110)  ·  Neoplasm Metastasis (901)  ·  Carcinoma, Non-Small-Cell Lung (828)  ·  Lung Neoplasms (778)  ·  Ovarian Neoplasms (715)  ·  Gastrointestinal Neoplasms (698)

Broader conditions

Digestive System Diseases (21776)  ·  Neoplasms by Site (21542)  ·  Neoplasms (20665)  ·  Gastrointestinal Diseases (14455)  ·  Gastrointestinal Neoplasms (13812)  ·  Intestinal Diseases (9493)  ·  Intestinal Neoplasms (9384)  ·  Rectal Diseases (7950)  ·  Colonic Diseases (7885)  ·  Neoplasms by Histologic Type (6358)  ·  Neoplasms, Glandular and Epithelial (5706)  ·  Carcinoma (5096)  ·  Endocrine System Diseases (4456)  ·  Endocrine Gland Neoplasms (4400)

Interventions

Oxaliplatin (1282)  ·  Fluorouracil (1220)  ·  Capecitabine (997)  ·  Gemcitabine (916)  ·  Leucovorin (869)  ·  Bevacizumab (813)  ·  Irinotecan (752)  ·  Cisplatin (617)  ·  Radiotherapy (521)  ·  Cetuximab (461)  ·  pembrolizumab (420)  ·  Paclitaxel (365)  ·  Nivolumab (318)  ·  Drug Therapy (317)  ·  Sorafenib (289)

Sponsors

National Cancer Institute (NCI) (483)  ·  Sun Yat-sen University (390)  ·  Fudan University (363)  ·  M.D. Anderson Cancer Center (288)  ·  Memorial Sloan Kettering Cancer Center (230)  ·  Hoffmann-La Roche (153)  ·  National Taiwan University Hospital (152)  ·  Shanghai Zhongshan Hospital (149)  ·  Tianjin Medical University Cancer Institute and Hospital (146)  ·  Seoul National University Hospital (145)  ·  Yonsei University (131)  ·  Samsung Medical Center (114)  ·  Assistance Publique - Hôpitaux de Paris (112)  ·  City of Hope Medical Center (109)  ·  Mayo Clinic (105)

Countries

United States (6808)  ·  China (5294)  ·  France (1605)  ·  South Korea (1454)  ·  Italy (1203)  ·  Spain (1127)  ·  United Kingdom (1027)  ·  Germany (1000)  ·  Canada (962)  ·  Taiwan (820)  ·  Japan (667)  ·  Netherlands (661)  ·  Belgium (628)  ·  Australia (550)  ·  Denmark (430)

Top investigators

Tim F Greten, M.D. (22)  ·  Ajay Goel, PhD (21)  ·  Ming Shi, MD (21)  ·  Norman Wolmark, MD (21)

Results publications

PMID 33538338, PMID 35623069, PMID 39863139, PMID 26808342, PMID 30207593, PMID 36306483, PMID 12049862, PMID 40341124, PMID 15496622, PMID 35588252, PMID 37162250, PMID 11981766, PMID 19192962, PMID 12540794, PMID 18650514, PMID 29433850, PMID 31268130, PMID 33356421, PMID 40340830, PMID 15273542, PMID 19095497, PMID 20375404, PMID 20728210, PMID 21561347, PMID 22646630, PMID 26049686, PMID 26187751, PMID 28712102, PMID 29628281, PMID 30679026, PMID 31378656, PMID 31401903, PMID 32402160, PMID 32816630, PMID 34143971, PMID 36852452, PMID 36990609, PMID 37598000, PMID 37934000, PMID 12091661, PMID 18316791, PMID 19097774, PMID 19269519, PMID 19339720, PMID 21374666, PMID 21596621, PMID 21997132, PMID 22070868, PMID 23433878, PMID 24131140

NIH funding

2023 (107), 2025 (75), 2019 (72), 2017 (68), 2015 (61), 2018 (61), 2016 (59), P30CA033572 (50), 2014 (48), 2009 (46), P30CA016672 (43), P30CA015083 (42), 2008 (37), P30CA014089 (34), U10CA032102 (32)